View Clinical Trial (Medical Research Study)

A Randomized Phase III Study of Vitamins B6 and B12 to Prevent Chemotherapy-Induced Neuropathy in Cancer Patients - NCT00659269-87131(Clinical Trial 215546)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Albuquerque
State:  
NM
Zip Code: 87131
Conditions: Chemotherapy-Induced Neuropathy in Cancer Patients
Purpose: Primary Objective:To determine the efficacy of the combination of vitamin B6 and B12 in preventing chemotherapy induced neuropathy
Study summary: Neuropathy can be a significant side effect of chemotherapy using platinum compounds, taxanes, and vinca alkaloids. There is clinical and preclinical data that vitamin B6 and B12 may alleviate neuropathy in experimentally induced neuropathy in animal models, or clinical neuropathy such as diabetic neuropathy. This is a randomized phase III study of the use of multivitamins with or without vitamin B6 and B12 to prevent or relieve neuropathic toxicity from chemotherapy in patients receiving chemotherapy. Patients will be stratified by type of chemotherapy agent (3 groups), presence or absence of neuropathy at baseline, and randomized to receive placebo or vitamin b6/b12 supplementation.
Criteria: Inclusion Criteria: 1. All patients, 18 years of age or older, with a cancer treated with any of the following drugs are eligible: - Taxanes, vinca alkaloid analogs, heavy metals. - Each patient will be allocated to the following 3 groups: - Group 1 (Heavy metals): Patients treated with cisplatin (>25 mg/m2/week dose intensity) or oxaliplatin - Group 2 (Taxane): Patients treated with paclitaxel, docetaxel or abraxane - Group 3 (Vinca alkaloids): Patients treated with vincristine and vinorelbine. 2. Patients must have a life expectancy of at least 24 weeks. 3. Patients must have a Zubrod performance status of 0-2. 4. Patients must sign an informed consent. 5. Patients may have a grade 0 (chemotherapy naive) or 1 neuropathy (history of prior chemotherapy) prior to entry. Exclusion Criteria: 1. Patients with symptomatic brain metastases are excluded from this study. 2. Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception. 3. Patients may receive no other concurrent complementary medicines during this study. 4. Patients with neuropathy induced diabetes are not eligible for this study 5. Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.
Study is available at: Universtiy of New Mexico Cancer Center
Albuquerque, NM 87131
United States

Primary Contact:
Valerie Parks
Email: vparks@salud.unm.edu
Phone: 505-925-0390

Secondary Contact:
Valerie Parks
Email: vparks@salud.unm.edu
Phone: 505-925-0390
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 22, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.